secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001193125-24-227977
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma prices $12M public offering of stock and warrants, extends cash runway into Q4 2025
--------------------------------------------------------------------------------

- 10.6M shares of common stock and 2.9M common stock warrants offered at $0.50 per unit; pre-funded warrants for 12.4M shares at $0.499.
- Net proceeds estimated at $10.7M after underwriting discounts and expenses.
- Oppenheimer & Co. is sole book-running manager; closing expected September 30, 2024.
- Cash runway extended into fourth quarter of 2025, based on current plans.
- Warrants: pre-funded exercisable at $0.001, common stock warrants at $0.50, expire in five years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/0001193125-24-227977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312524227977/d856255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-227977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer